Intuitive Surgical procedure outlook likely conservative, says Jefferies Jefferies says that while Intuitive Surgical's lack of revenue and earnings guidance is indicative of near-term headwinds and uncertainties, its procedure guidance met expectations and is likely conservative. The firm believes Intuitive's long-term growth prospects remain compelling and it keeps a Buy rating on the stock with a $480 price target following the company's Q4 results.
Intuitive Surgical initiated with a Neutral at Piper Jaffray Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.